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Plexus choroideusIntracerebral accumulation of neurotoxic dicarboxylic acids (DCAs) plays an important pathophysiological
role in glutaric aciduria type I and methylmalonic aciduria. Therefore, we investigated the transport
characteristics of accumulating DCAs – glutaric (GA), 3-hydroxyglutaric (3-OH-GA) and methylmalonic acid
(MMA) – across porcine brain capillary endothelial cells (pBCEC) and human choroid plexus epithelial cells
(hCPEC) representing in vitro models of the blood–brain barrier (BBB) and the choroid plexus respectively.
We identiﬁed expression of organic acid transporters 1 (OAT1) and 3 (OAT3) in pBCEC on mRNA and protein
level. For DCAs tested, transport from the basolateral to the apical site (i.e. efﬂux) was higher than inﬂux.
Efﬂux transport of GA, 3-OH-GA, and MMA across pBCEC was Na+-dependent, ATP-independent, and was
inhibited by the OAT substrates para-aminohippuric acid (PAH), estrone sulfate, and taurocholate, and the
OAT inhibitor probenecid. Members of the ATP-binding cassette transporter family or the organic anion
transporting polypeptide family, namely MRP2, P-gp, BCRP, and OATP1B3, did not mediate transport of GA,
3-OH-GA or MMA conﬁrming the speciﬁcity of efﬂux transport via OATs. In hCPEC, cellular import of GA was
dependent on Na+-gradient, inhibited by NaCN, and unaffected by probenecid suggesting a Na+-dependent
DCA transporter. Speciﬁc transport of GA across hCPEC, however, was not found. In conclusion, our results
indicate a low but speciﬁc efﬂux transport for GA, 3-OH-GA, and MMA across pBCEC, an in vitro model of the
BBB, via OAT1 and OAT3 but not across hCPEC, an in vitro model of the choroid plexus.d–cerebrospinal ﬂuid barrier;
, initial concentration; 14C-GA,
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Accumulation of characteristic neurotoxic dicarboxylic acids
(DCAs) is the common biochemical hallmark of glutaric aciduria
type I (GA-I; MIM # 231670) and methylmalonic aciduria (MMAuria;
MIM # 251000, 277400, 251100, 277410, 251110, 277380, and
606169), two inherited organic acidurias. GA-I is an autosomal
recessive defect of glutaryl-coenzyme A (CoA) dehydrogenase
(GCDH, EC 1.3.99.7), a central enzyme in the distal catabolic pathways
of L-lysine, L-tryptophan, and L-hydroxylysine catalyzing the oxidative
decarboxylation of glutaryl-CoA to crotonyl-CoA and CO2. GCDH
expression has been demonstrated in brain, liver and kidney with the
highest activity in the latter two tissues [1,2]. The clinical presentation
of untreated patients is characterized by the onset of acute striatal
injury during encephalopathic crises. These crises are precipitated by
episodes that are likely to induce catabolic state such as intercurrent
febrile illnesses during a vulnerable period of brain development in
infancy [3,4]. Affected patients display elevated levels of glutaric acid
(GA) and 3-hydroxyglutaric acid (3-OH-GA) in serum and urine. Post
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deﬁcient mice showed massive accumulation of GA and 3-OH-GA in
brain tissue (up to 10 nmol GA/mg protein and 0.5 nmol 3-OH-GA/
mg protein) [2,5].
MMAuria is an etiologically heterogeneous group of metabolic
disorders caused by inherited deﬁciency of the mitochondrial
enzyme methylmalonyl-CoA mutase (MCM; EC 5.4.99.2) or by
defects in the uptake, transport, or synthesis of its cofactor 5′-
deoxyadenosylcobalamin. MCM catalyzes the conversion of methyl-
malonyl-CoA to succinyl-CoA linking the ﬁnal degradative pathways
of branched-chain amino acids, odd number fatty acids, and the
cholesterol side chain to the tricarboxylic acid cycle.MCMis alsopresent
in the brain, whereas highest tissue-speciﬁc MCM activity is found in
liver and kidneys [6]. The disease course is characterized by acute
metabolic crises during catabolic state that can result in multiple-organ
failure or even death. Major long-term complications are severe
neurological deﬁcits, chronic renal failure, cardiomyopathy, and
pancreatitis [7,8]. Among them, neurological symptoms such as
extrapyramidal movement disorders, psychomotor retardation and
epileptic seizures are most frequently found [9]. Biochemically,
MMAuria is characterized by the accumulation of the name-giving
DCAmethylmalonic acid (MMA), metabolites deriving from alternative
oxidation pathways of propionyl-CoA, such as 3-hydroxypropionic acid
and 2-methylcitric acid, as well as the glycine and carnitine conjugates
propionylglycine and -carnitine [10].
Cerebral impairment in GA-I and MMAuria is currently understood
to be induced by synergistic intracellular and extracellular toxic effects
of accumulating organic acids and CoA esters causing mitochondrial
dysfunction and, subsequently, impaired energy metabolism (GA-I,
[2,13,14]; MMAuria, [11,12]).
Understanding the origin (e.g. liver, kidney or central nervous
system [CNS]) of cerebrally accumulating neurotoxic DCAs is essential
for designing therapeutic strategies ranging from dietary restriction of
precursor amino acids of neurotoxic DCAs and pharmacological
activation of the formation of non-toxic acylcarnitines [15] to invasive
therapies such as liver or combined liver/kidney transplantation [16].
In GA-I, it has been originally hypothesized that GA and 3-OH-GA [17]
are produced in the liver and are transported into the brain via the
blood–brain barrier (BBB). However, we have found preliminary
evidence that the BBB is only weakly permeable for GA and 3-OH-GA
[2]. Due to the fact that GA-I patients and Gcdh-deﬁcient mice display
GA and 3-OH-GA concentrations in the brain that exceed plasma
levels 10–10,000times [2,5], we have hypothesized that GA and 3-OH-
GA are de novo synthesized in the CNS and are intracerebrally trapped
due to limited efﬂux (so-called ‘trapping hypothesis’) [2,18].
Importantly, the BBB remains intact and is weakly permeable for GA
and 3-OH-GA while inducing metabolic crises and striatal injury in
Gcdh-deﬁcient mice [19]. For MMAuria, however, nothing is as yet
known whether the BBB is involved in the neuropathogenesis.
The blood–cerebrospinal ﬂuid (CSF) barrier (BCB), i.e. the choroid
plexus, is the second important metabolic barrier of the brain. Uptake
of DCAs at the CSF site of the choroid plexus has previously been
described [20]. However, little is known about the role of this barrier
in organic acidurias. Although the surface area of the choroid plexus is
several thousand times smaller than the surface area of the BBB [21],
transport of toxic DCAs may occur via this route.
Since it is of pathophysiological and therapeutic importance to
understand cerebral import and export of GA, 3-OH-GA, and MMA
across the BBB and BCB, our study aims to identify transport systems
that may mediate this transport. Putative candidates for the transport
of DCAs across the BBB are members of the SLC22 (organic acid
transporter [OAT] 1–4; [22]) and SLC13 (Na+-dependent DCA
transporter [NaDC] 1–3; [23]) families that have been shown to
transport DCAs in different tissues and cell types. It has been recently
postulated that OAT1 and OAT4 mediate the high afﬁnity transport of
GA derivatives in proximal tubular kidney cells [24]. Though organicanion transport via OATs at the BBB has been indicated [25], only
expression of OAT3 has as yet been functionally demonstrated at the
BBB [26,27].2. Experimental procedures
2.1. RT-PCR
First, we investigated the mRNA expression of candidate DCA
transporters by RT-PCR studies in porcine brain capillary endothelial
cells (pBCEC). Due to the fact that the porcine genome has not yet
been completely sequenced, we used sequence speciﬁc primers for
cDNAs of the corresponding human (h) protein except for the porcine
(ss) OAT3 cDNA that has recently been published. Since the proximal
renal tubule has been shown to express OAT1–4 as well as NaDC1 and
NaDC3 [28] we used homogenate from proximal tubule of porcine
kidney to conﬁrm the speciﬁcity of our primers. Total RNA was
prepared from pBCEC and proximal tubule cells by RNeasy mini kit
(Qiagen). First-strand cDNA was synthesized from 2 μg of RNA using
SuperScript III and RNase OUT (Invitrogen) with random hexamer
primers. PCR was performed using Failsafe™ PCR-system from
Epicentre Biotechnologies (denaturation step, 30 s at 94 °C; annealing
step, 30 s at 54 °C; elongation step, 2 min at 72 °C). The following
primers were used:Protein Reverse primer (5′ to 3′) Forward primer (5′ to 3′) Predicted
sizehOAT1 CTGGGGAACTGTATCCCACA GGTTCTTCATTGAGTCGGCCC 517 bp
hOAT2 CTGTGCCTGCCTCGTCTCTG CCAGGAGGCTGTGAGCAAAGTG 592 bp
ssOAT3 CAGGAAGAGGGCAGCACTG CACCGCAAGTGACCTGTTCC 521 bp
hOAT4 GTCAGGTTCTTGGCCTCCTTG ATGCTGGACAATGGCTCTGC 758 bp
hNaDC1 TGGGGGAAGAGCGAGTTGA CCCTTAATCCTGTTCCCTATGA 562 bp
hNaDC3 GACGGGAAGAAGAACAAGATGG CACCGCCTCCACTGCCATGAT 749 bp2.2. Western blotting
To investigate OAT1 and OAT3 protein expression in pBCEC we used
polyclonal antibody against the carboxy terminus of these transporters
(anti-OAT1, rabbit anti-rat, Alpha Diagnostic, San Antonio, USA, 1:1000,
diluted in blocking solution containing 4% [v/v] of nonfat dry milk in
Tris-buffered saline Tween-20 (TBST); anti-OAT3, mouse anti-human,
Abcam, 1:250 diluted in blocking solution). Cellswerewashedwith pre-
warmed phosphate-buffered saline and incubated for 10 min with a
trypsin solution at 37 °C. Afterwards cells were centrifuged at 1000×g
for 10 min. The cell pellet was washed twice with phosphate-buffered
saline and dispensed in RIPA buffer containing 150 mmol/L NaCl,
50 mmol/L Tris–HCl (pH 8.0), 1% NP-40, 0.5% sodium deoxycholate
1 mmol/L sodium vanadate, 5 mmol/L sodium ﬂuoride and 1 mmol/L
phenylmethylsulfonyl ﬂuoride. Cells were disrupted using a Becton
Dickinson 22 G×1.25 needle and were incubated on ice for 1 h. To
separate solubilized membrane proteins from membrane debris, the
homogenate was centrifuged for 10 min at 11,000 ×g at 4 °C in an
Eppendorf centrifuge. The supernatant was diluted in sodium dodecyl
sulfate (SDS) sample buffer (0.5 mol/L Tris–HCl, pH 6.8, 10% glycerol,
1% SDS and 0.01% bromophenol blue). Expression of OAT1 and OAT3
was independently studied. Samples containing 20 μg of protein were
applied to a 7.5% gel, separated by SDS-polyacrylamide gel electropho-
resis, and then electroblotted to polyvinylidene ﬂuoride membranes
which were previously incubated in blocking solution for 1 h to
minimize non-speciﬁc binding of antibodies. The membrane was then
incubated with the primary antibody at 4 °C over night. After being
rinsed with TBST, membranes were incubated for 2 h with the
secondary horse-radish peroxidase-labeled antibody (anti-mouse,
anti-rabbit, 1:10,000 diluted in blocking solution, Southern Biotech,
Birmingham, USA). After being again rinsed with TBST blots were
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chemiluminescent detection reagents.
2.3. Transport of DCAs across cultured pBCEC
Primary cultures of pBCEC were prepared as described previously
[2]. Cortical gray matter from fresh porcine brains was minced and
digested enzymatically using 0.5% dispase II (Cat. Nr. 04 942 078 001,
Hoffmann LaRoche, Mannheim, Germany). Cerebral microvessels
were obtained after centrifugation in 15% dextran and were subse-
quently incubated in a buffer containing 1 mg/mL collagenase/
dispase. The resulting cell suspension was supplemented with 10%
horse serum and ﬁltered through 150-μm nylon mesh, and pBCEC
were separated on a continuous Percoll™ gradient at concentrations of
1.03 g/mL (20 mL) and 1.07 g/mL (15 mL) (Pharmacia, Uppsala,
Sweden). Isolated pBCEC were ﬁltered through a 35-μm nylon mesh
before being seeded, at a density of 250,000 cells/cm2, onto collagen
(Cat. Nr. 11 179 179001, Roche,Mannheim,Germany)-coatedﬁlters in
12-well cell culture plates. Cells were cultivated in Medium 199
containing 100 μg/mL streptomycin, 100 μg/mL penicillin G,
10 mmol/L HEPES, 10% heat-inactivated horse serum, and 0.8 mmol/
L L-glutamine (all from Biochrom, Berlin, Germany). After reaching
conﬂuency, medium was changed at 6th day in culture and cells were
grown in 45% MEM, 45% F12-HAM, 100 μg/mL streptomycin, 100 μg/
mL penicillin G, 10 mmol/L HEPES, 2 mmol/L L-glutamine (all from
Biochrom). At the following day, medium was removed from both
compartments of the chamber and cells were washed twice with a
Krebs–Ringer buffer (KRB; 115 mmol/L NaCl, 5.9 mmol/L KCl,
1.2 mmol/L MgCl2, 1.2 mmol/L NaH2PO4, 1.2 mmol/L Na2SO4,
2.5 mmol/L CaCl2, 25 mmol/L NaHCO3, 10 mmol/L glucose, pH 7.4
and 37 °C) and were subsequently used for the transport experiments.
Transport of d4-glutaric acid (d4-GA), d5-3-hydroxyglutaric acid
(d5-3-OH-GA), or d3-methylmalonic acid (d3-MMA; each 0.1–
1 mmol/L in KRB) was characterized with regard to inﬂux (transport
into the brain) and efﬂux (transport out of the brain) and whether it
wasNa+- and energy-dependent aswell as competitively inhibitable by
the OAT1 and 3 substrate para-aminohippuric acid (PAH; 4 mmol/L). In
Na+-free KRB, Na+was substituted with an equimolar concentration of
n-methylglucamine (NMG). To reduce mitochondrial ATP production,
NaCN (2 mmol/L) was added to the transport buffer. For ﬂuorescein
transport studies, wells were washed twice with KRB. Fluorescein
(1 μmol/L in KRB)was added to the same compartment of the chamber
as the before tested DCAs without variation of the standard transport
conditions, i.e. only in presence of KRB. Cells were incubated for 90 min
(37 °C) and 200 μL of buffer were removed from the acceptor
compartment after 30 min, 60 min, and 90 min. The concentrations of
d4-GA, d5-3-OH-GA, and d3-MMA were analyzed by gas chromatogra-
phy/mass spectrometry. Fluorescein was detected using a Tecan™
ﬂuorometer.
Using the same in vitro systemwe studied also time dependence of
basolateral 14C-GA (100 μmol/L; speciﬁc activity, 0.1 μCi/nmol)
uptake and basolateral 14C-GA uptake in the presence of the OAT1
and 3 substrate estrone sulfate, the OAT3 substrate taurocholate, and
the OAT1 and 3 inhibitor probenecid (each 1 mmol/L). After
incubation with 14C-GA cells were washed twice with ice cold KRB,
harvested with 0.1 mol/L NaOH and intracellularly trapped 14C-GA
was detected by a scintillation counter (LS6500 Beckman Coulter).
The apparent permeability coefﬁcient (P) was calculated according







∂Q/∂t, Change of concentration of GA, 3-OH-GA or MMA in the
acceptor compartment as a function of time; A, surface area of theﬁlter (1.1 cm²); Vac, volume of the acceptor compartment; C0, initial
concentration of GA, 3-OH-GA or MMA in the donor compartment.
2.4. Quantitative analysis of d4-GA, d5-3-OH-GA, and d3-MMA
d4-GA, d5-3-OH-GA, and d3-MMA were detected as previously
described using gas chromatography/mass spectrometry with stable-
isotope dilution assay [2].
2.5. Multidrug resistance protein 2 (MRP2) assay
GA, 3-OH-GA and MMA were tested for interaction with MRP2
transporter as previously described [29]. Brieﬂy, Caco2 cells over-
expressing MRP2 were seeded at a density of 80,000 cells/well in 96-
well plates and incubated in DMEM supplemented with 3.7 g/L
NaHCO3, 4.5 g/L glucose, stable glutamine (2 mmol/L), FCS (10%),
penicillin/streptomycin (100 U/mL; 100 μg/mL), non-essential
amino acids (1%) and sodium pyruvate (1 mmol/L) (all from
Biochrom, Berlin, Germany) for three weeks. Subsequently, cells
were washed twice with 37 °C warm KRB and incubated simulta-
neously with 1 μmol/L 5-chloromethylﬂuorescein-diacetate and
testing substances (up to 1 mmol/L in KRB; pH 7.4). The MRP2
inhibitor MK571 (50 μmol/L) was used as positive control. The non-
ﬂuorescent, lipophilic ﬂuorescein derivate 5-chloromethylﬂuores-
cein-diacetate permeates the cell membrane and is intracellularly
cleaved by non-speciﬁc esterases into the hydrophilic ﬂuorescent
intermediate chloromethylﬂuorescein. The chloromethyl residues
react with the thiol groups of glutathione resulting in the highly
hydrophilic ﬂuorescent MRP2 substrate glutathione methylﬂuores-
cein. After incubation cells were washed twice with ice cold KRB and
lysed with 1% Triton X-100 in KRB. Intracellularly accumulated
ﬂuorescence was measured using a Fluoroscan Ascent™ plate reader
(ThermoElectron, Dreieich, Germany) with excitation at λ=485 nm
and emission at λ=520 nm. To exclude false negative results
substances were tested for esterase inhibition. Results are given as
percentage of ﬂuorescence in the control.
2.6. Breast cancer resistance protein (BCRP) assay
The interacting potency of GA, 3-OH-GA and MMA with BCRP
efﬂux activitywas studied in pBCEC usingmitoxantrone as ﬂuorescent
substrate [30]. pBCEC were incubated for 1 h in DMEM/Ham's F12 1:1
(Biochrom, Berlin, Germany) at a density of 2.5×107 cells/mL.
Afterwards, 600 μL of cell suspension were incubated simultaneously
with 15 μmol/L mitoxantrone and test compounds (up to 1 mmol/L
in DMEM/Ham's F12; pH 7.4) for 1 h at 37 °C. The speciﬁc BCRP
inhibitor fumitremorgin C (10 μmol/L) was used as positive control.
Subsequently, cells were centrifuged at 200×g for 5 min and were
washed twice with ice cold KRB. Intracellular mitoxantrone ﬂuores-
cence was measured using a FACS Calibur ﬂow cytometer (Becton
Dickinson, Franklin Lakes NJ, USA) equipped with a 635 nm red diode
laser and 670 nm bandpass ﬁlter. By gating on forward and side
scatter, endothelial cells were separated from debris and dead cells
were excluded likewise using propidium iodide staining. Twenty
thousand cells were sorted in one run. Data were processed and
analyzed with CellQuest™ Pro (Becton Dickinson).
2.7. P-glycoprotein (P-gp) assay
Modulatory effects on P-gp transport function were examined in
pBCEC using calcein-AM as substrate [31]. pBCEC were cultivated as a
monolayer as described above and were washed twice with 37 °C
warm KRB. Afterwards, cells were preincubated with 100 μL of test
compound (up to 1 mmol/L in KRB; pH 7.4) for 15 min at 37 °C
followed by addition of a calcein-AM solution (1 μmol/L) incubation
for 30 min. The non-ﬂuorescent lipophilic ester calcein-AM diffuses
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Competitive inhibition of P-gp by the tested DCAs will result in
increasing intracellular calcein-AM levels where it is hydrolysed by
non-speciﬁc esterases into the ﬂuorescent dye calcein. Cells were
washed twice with ice cold KRB and intracellular ﬂuorescence was
measured after 30 min cell lyses with 1% Triton X-100 using a
Fluoroscan Ascent™ plate reader (excitation at λ=485 nm and
emission at λ=520 nm). The calcium-channel antagonist verapamil
(100 μmol/L) was used as positive control.
2.8. Organic anion transporting polypeptide (OATP) 1B3 assay
Inhibition of OATP1B3-mediated intracellular uptake of Fluo-3 due
to GA, 3-OH-GA or MMA was tested according to Baldes et al. [32].
Brieﬂy, OATP1B3-transfected human embryonic kidney cells, which
were kindly provided by Prof. Dr. Dietrich Keppler (German Cancer
Research Center, Division of Tumor Biochemistry, Heidelberg,
Germany), were seeded in 24-well plates at a density of 4×105
cells/well and exposed to 10 mmol/L sodium butyrate 24 h prior to
the experiment. Immediately before the uptake experiment, cells
were washed with 37 °C warm uptake buffer (consisting of
142 mmol/L NaCl, 5 mmol/L KCl, 1 mmol/L KH2PO4, 1.2 mmol/L
MgSO4, 1.5 mmol/L CaCl2, 5 mmol/L glucose and 12.5 mmol/L HEPES,
pH 7.4) and were incubated with 500 μL of corresponding test
compounds (up to 1 mmol/L in uptake buffer; pH 7.4) for 1 h.
Subsequently, cells were incubated with 2 μmol/L Fluo-3 in the
presence of test substances for an additional hour. Finally, cells were
washed twice with ice cold uptake buffer and lysed with 0.05% SDS in
a 1 mmol/L CaCl2 solution. Intracellularly accumulated ﬂuorescence
was quantiﬁed with a Fluoroscan Ascent™ plate reader (excitation at
λ=485 nm and emission at λ=530 nm). The degree of uptake
inhibition is inversely related to intracellularly trapped Fluo-3.
Bromosulfophthalein (1 μmol/L) was used as positive control.
2.9. Cytoxicity assay
To investigate the impact of d4-GA, d5-OH-GA, and d3-MMA on cell
viability, an assay using tetrazolium salt 3-[4,5-dimethylthiazolyl-2]-
2,5-diphenyltetrazolium bromide (MTT) was performed. The MTT
assay was purchased from Sigma Aldrich (Taufkirchen, Germany) and
carried out according to the manufacturer's manual. Cells were
incubated with different concentrations of d4-GA, d5-3-OH-GA, and
d3-MMA (0.1, 1, 5 mmol/L) for 7 days. The protein synthesis inhibitor
cycloheximide (25 μmol/L) and the apoptotic agent tert-butyl-
hydroperoxid (750 μmol/L) were used as positive controls.
2.10. Transport of 14C-GA in primary cultures from human choroid
plexus epithelial cells (hCPEC)
hCPEC were purchased from Sciencell (Carlsbad, USA) and
cultivated in Epicem medium supplemented with 10% heat-inacti-
vated FCS, 100 U/mL penicillin, 0.1 mg/mL streptomycin and a
mixture of growth supplements. Cells were grown in poly-L-lysine-
coated T75 culture ﬂasks. For transport studies cells were subse-
quently harvested at a conﬂuence of 70% using accutase and
centrifuged for 10 min at 1000×g. Cells were counted and plated
onto poly-L-lysine-coated Transwell ﬁlters (60,000 cells per well) at
37 °C for 48 h. Uptake of 14C-GA and time-dependent transport of 14C-
GA across hCPEC was characterized including the investigation of
energy and sodium dependency (as described above for pBCEC) as
well as its competition with probenecid (2 mmol/L). The apical
compartment of the chamber represents the CSF site and the
basolateral compartment represents the blood site. Cells were
harvested using 100 μL NaOH (0.1 mol/L) per well. 14C-GA was
detected using a scintillation counter (LS6500 Beckman Coulter).2.11. Statistical analysis
All experiments were performed at least in triplicates. If more than
three independent experiments have been performed, this is
explicitly stated. Data were expressed as mean±S.D. if not indicated
differently. For pairwise andmultiple comparisons Student's t test and
ANOVA with Bonferroni adjustment respectively were calculated.
Time-dependent transport studies with and without the addition of
inhibitors were evaluated using ANOVA repeated measures. All
statistics were calculated in SPSS for Windows 16.0 Software.
pb0.05 was considered as signiﬁcant.
3. Results
3.1. RT-PCR and protein expression of putative DCA transporters in
pBCEC
The control RT-PCR in homogenate from porcine proximal tubule
revealed speciﬁc bands for OAT1, OAT3, NaDC1, and NaDC3 with the
predicted sizes (Fig. 1a). RT-PCR studies in pBCEC identiﬁed speciﬁc
products for hOAT1 and ssOAT3 but revealed no PCR products for
hNaDC1, hNaDC3, hOAT2, and hOAT4. Whereas the ssOAT1 product
(480 bp) had almost the predicted size (517 bp), the ssOAT3 product
(1.4 kb) was three times larger than the predicted product (521 bp;
Fig. 1b). The same result was repeated in three independent
experiments. Sequence analysis underlined the speciﬁcity of the
product showing that a 150 bp sequence at the 3′ end and a 105 bp
sequence at the 5′ end is 92% and 93% respectively identical to the
corresponding porcine cDNA sequence. For a full sequence analysis of
the PCR product, it was subcloned in E. coli using a pGEM®-T-Easy
vector system (Promega). The full sequence (1.4 kb) of the PCR
product shared a 75% similarity to the human OAT3 mRNA indicating
that the protein expressed in pBCEC is a splice variant to the originally
published sequence.
In Western blot analysis, the antibody against OAT3 detected a
speciﬁc band with a molecular mass of approximately 62 kD
corresponding to the OAT3 protein [26]. Using an antibody against
OAT1 we found a protein product with a molecular mass of
approximately 57 kD as previously described ([33]; Fig. 1c).
3.2. Characterization of DCA transport in pBCEC
First, we investigated the transport of d4-GA, d5-3-OH-GA, and d3-
MMA (each up to 1 mmol/L) from the basolateral compartment of the
chamber to the apical compartment (simulating efﬂux from brain to
blood) and vice versa (simulating inﬂux from blood to brain). Efﬂux of
all tested DCAs was signiﬁcantly higher than their inﬂux (Fig. 2; n=6
independent experiments, pb0.05). To describe the efﬂux transport in
further detail all subsequent experiments were carried out as efﬂux
experiments.
We tested whether efﬂux transport of d4-GA, d5-3-OH-GA, and d3-
MMAwas dependent on Na+ and ATP, and whether it competed with
PAH, a known OAT substrate. d4-GA, d5-3-OH-GA, and d3-MMA
revealed the same transport characteristics in our experiments. Efﬂux
transport of these DCAs (each 100 μmol/L) was inhibited by PAH
(4 mmol/L) and was decreased when Na+ was replaced by NMG. In
contrast, addition of the cytochrome c oxidase inhibitor NaCN
(2 mmol/L) did not inﬂuence the efﬂux of these compounds
indicating that it was not energy-dependent (d4-GA: Fig. 3a; d5-3-
OH-GA: Fig. 3b; d3-MMA; Fig. 3c). The results suggested that efﬂux
transport of d4-GA, d5-3-OH-GA, and d3-MMA is mediated by OAT1
and OAT3.
To reﬁne our ﬁndings, we investigated time-dependent basolateral
14C-GA (100 μmol/L; speciﬁc activity, 0.1 μCi/nmol) uptake. 14C-GA
uptake was described by a Michaelis–Menten-like kinetic with the
highest import rate within the ﬁrst 10 min and a reduced but linear
Fig. 2. Transport of DCAs across pBCEC: inﬂux versus efﬂux in pBCEC. Efﬂux of d4-GA, d5-
3-OH-GA, and d3-MMA (each 1 mmol/L; transport from the basolateral compartment
of the chamber to the apical compartment) was signiﬁcantly higher than inﬂux (n=6
independent experiments; *pb0.05 vs. inﬂux, Student's t test). Efﬂux and inﬂux of DCAs
are presented as apparent permeation coefﬁcient. Data are expressed as mean±S. D.
Fig. 1. a,b,c RT-PCR and protein expression of putative DCA transporters. mRNA was
isolated from pBCEC and porcine proximal tubule and reverse-transcribed. The reaction
products were then used as template for PCR using speciﬁc primers for hOAT1, hOAT2,
hOAT3, hOAT4, hNaDC1, hNaDC3, ssOAT3. 1a) porcine proximal tubule; lane 1, OAT3; lane
2, OAT1; lane3, NaDC1; lane 4, NaDC3; lane 4, OAT4. A 1 kb ladder ﬂanks the experimental
lanes. 1b) pBCEC; Lane 1, OAT1; lane 2, OAT2, lane 3, empty; lane 4, OAT3; lane 5, OAT4;
lane 6, NaDC1; lane 7, NaDC3. Lanes containing a 100-bp and 1.5 kb ladder ﬂank the
experimental lanes. PCR products were obtained for hOAT1 and ssOAT3. 1c) Expression of
OAT1 and OAT3 was further investigated by Western blotting showing speciﬁc bands for
both proteins (two independent experiments per antibody) using 250 ng of protein and,
additionally, 350 ng of protein for OAT3 due to the weaker band.
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amount of 14C-GA that was transported across pBCEC in these
experiments. The transport rate was in the same range as shown for
d4-GA and linear over the whole incubation period (Fig. 4b). A
comparison of cellular uptake and transcellular transport kinetics
showed that GA is transported into the cell but accumulates
intracellularly due to weak efﬂux. Next, we studied the basolateral
uptake of 14C-GA (100 μmol/L; speciﬁc activity, 0.1 μCi/nmol) in the
presence of the OAT1 and 3 substrate estrone sulfate, the OAT1 and 3
inhibitor probenecid, and the OAT3 substrate taurocholate (each
1 mmol/L; incubation time 10 min). Probenecid and estrone sulfate
showed a signiﬁcant cis-inhibitory effect on 14C-GA uptake (uptake
inhibition, 50% and 48% respectively; pb0.05; Fig. 4c). The inhibitoryeffect of taurocholate was less pronounced (uptake inhibition, 26%;
pb0.05; Fig. 4c).
3.3. Transport of ﬂuorescein across pBCEC
To investigate whether DCAs were trapped in pBCEC during
transport studies as indicated by the 14C-GA uptake experiment, we
determined the efﬂux of the OAT1 and 3 substrate and monocarbox-
ylic acid ﬂuorescein across pBCEC immediately after these cells were
preconditioned by the above described DCA transport studies. Loading
of pBCEC with DCAs will stimulate the uptake of the monocarboxylic
acid ﬂuorescein in a concentration-dependent way via anion
exchange. Fluorescein (1 μmol/L) transport across pBCEC was
monitored for 90 min and was approximately two times higher than
the transport of d4-GA, d5-3-OH-GA, and d3-MMA. As expected, efﬂux
transport of ﬂuorescein was highest in those wells previously
incubated with d4-GA, d5-3-OH-GA, or d3-MMA alone (pb0.05 vs.
control). Fluorescein transport was not or only mildly increased in
wells with previously inhibited DCA transport, i.e. cis-inhibition with
PAH and replacement of Na+ with NMG (Fig. 5). Efﬂux of ﬂuorescein
was also inhibited after preconditioning with NaCN in combination
with GA, 3-OH-GA orMMA suggesting that the ﬂuorescein transport is
at least partially energy-dependent (Fig. 5).
3.4. DCAs are not transported via MRP2, P-gp, BCRP, and OATP1B3
To exclude that members of the ATP-binding cassette transporter
family or the organic anion transporting polypeptide family mediate
the transport of d4-GA, d5-OH-GA, and d3-MMA, we performed
transport studies with selectedmembers of these transporter families,
i.e. MRP2, P-gp, BCRP, and OATP1B3. Speciﬁc inhibitors for these
transporters – BCRP, fumitremorgin C (10 μmol/L); P-gp, verapamil
(100 μmol/L); OATP1B3, bromosulfophthalein (1 μmol/L); MRP2,
MK571 (50 μmol/L) – signiﬁcantly reduced their activity, whereas
d4-GA, d5-OH-GA, and d3-MMA (up to 1 mmol/L each) had no effect
(Fig. 6). This result shows that GA, 3-OH-GA, and MMA are no
substrates for the tested ATP-binding cassette transporters and
organic anion transporting polypeptide.
3.5. Cytotoxicity assay
BBB breakdown reduces or even eliminates the metabolic
separation of blood and brain. Therefore we investigated whether
Fig. 3. a,b,c Characterization of efﬂux transport of GA, 3-OH-GA, andMMA in pBCEC.We
investigated whether efﬂux transport of d4-GA (a), d5-3-OH-GA (b), and d3-MMA (c)
across pBCECwas dependent on Na+ and energy andwhether it was altered by the OAT
substrate PAH. For d4-GA, d5-3-OH-GA and d3-MMA (each 100 μmol/L) the same
transport characteristics were identiﬁed: 1) inhibition in the absence of Na+ (using
replacement with NMG) 2) inhibition by the OAT substrate PAH (4 mmol/L), 3) no
impairment by the cytochrome c oxidase inhibitor NaCN (2 mmol/L). Data are
presented as permeation over the time and, for legibility, are expressed as mean;
n=3 independent experiments. *pb0.05 vs. control (i.e. efﬂux transport of GA [a], 3-
OH-GA [b] or MMA [c] alone; ANOVA repeated measures); C0, initial concentration of
DCA in the donor compartment.
Fig. 4. a,b,c Characterization of cellular 14C-GA uptake in pBCEC. Uptake of 14C-GA
(100 μmol/L; speciﬁc activity, 0.1 μCi/nmol) revealed a Michaelis–Menten-like kinetic
(a). The simultaneously detected transport rate of 14C-GA across pBCEC was linear during
incubation time (b). Basolateral 14C-GA uptake was inhibited by probenecid, estrone
sulfate and – less pronounced – by taurocholate (each 1 mmol/L; incubation time, 10 min;
*pb0.05 vs. control, Student's t test; c). 14C-GA uptake is expressed as counts per minute
detected in the cell over the time and 14C-GA transport across pBCEC as permeation over
the time. Inhibition studies display the amount of imported 14C-GA expressed in CPM. All
data are presented as mean±S. D; C0, initial concentration of 14C-GA in the donor
compartment.
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apoptotic agent tert-butylhydroperoxide (25 μmol/L; for 3 days) and
the protein synthesis inhibitor cycloheximide (50 μmol/L; for 24 h)were used as positive controls. Both strongly reduced the cell viability
of pBCEC (n=4 independent experiments; pb0.05). In contrast,
incubation of up to 7 days with GA, 3-OH-GA or MMA (up to 5 mmol/
L each) did not reduce cell viability — except for the highest,
supraphysiological concentration of MMA tested (5 mmol/L; Fig. 7).
Fig. 5. Characterization of ﬂuorescein transport. Efﬂux transport of ﬂuorescein was
investigated in pBCEC immediately after transport studies with d4-GA, d5-3-OH-GA, or
d3-MMA had been ﬁnished (see Fig. 3). To test whether pBCEC are loaded with d4-GA,
d5-3-OH-GA, or d3-MMA after DCA transport studies, the efﬂux transport of ﬂuorescein
(1 μmol/L) was studied without addition of an activating or inhibiting agent. In
comparison to untreated control, efﬂux transport of ﬂuorescein was increased in pBCEC
after pre-incubation with d4-GA, d5-3-OH-GA, or d3-MMA alone (*pb0.05 vs. control,
ANOVA with Bonferroni adjustment). In contrast, ﬂuorescein transport was not
signiﬁcantly increased if DCA transport was previously impaired by cis-inhibition
with PAH and replacement of Na+ by NMG (see Fig. 3). In contrast to transport studies
with DCAs, efﬂux of ﬂuorescein was not increased in cultures preconditionedwith DCAs
and NaCN suggesting an energy-dependent mechanism for ﬂuorescein transport. Data
are expressed as apparent permeation coefﬁcient and are presented as mean±S. D.
Fig. 7. Cytoxicity studies inpBCEC. Cytotoxic effectswere studiedbyMTT assay. Incubation
of pBCEC with GA, 3-OH-GA or MMA up to 7 days (each 0.1, 1, and 5 mmol/L) did not
reduce cell viability – except for the highest, supraphysiological concentration of MMA
tested (5 mmol/L; *pb0.05 vs. control, ANOVA with Bonferroni adjustment). In contrast,
tert-butylhydroperoxide (25 μmol/L; for 3 days) and cycloheximide (50 μmol/L; for 24 h)
which were used as positive controls, strongly decreased cell viability (*pb0.05 vs.
control). Cell viability is presented asmean absorption of theproduced formazan dye. Data
are expressed as mean±S. D.; n=4 independent experiments.
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Next we studied the transport of 14C-GA (100 μmol/L; speciﬁc
activity, 0.1 μCi/nmol) across hCPEC. DCA transporters (OAT1 and 3;
NaDC1 and 3) have been shown to be exclusively expressed at the CSF
site of the choroid plexus [20]. In line with this ﬁnding, permeation
of 14C-GA from the CSF site to the blood site of the chamber
(representing efﬂux; apparent permeability coefﬁcient: 2.6×10−5±
6.9×10−6 cm/s) was 4.4 times higher than the reverse transport
(representing inﬂux; apparent permeability coefﬁcient: 5.9×10−6±
3.4×10−6 cm/s). Therefore, we further investigated DCA efﬂux.
Uptake of 14C-GA (20 min incubation) at the CSF site was dependentFig. 6. DCAs are not transported via MRP2, P-gp, BCRP, and OATP1B3. To test whether
d4-GA, d5-OH-GA, and d3-MMA were transported via alternative routes, we performed
speciﬁc transport studies with selected members of the ATP-binding cassette
transporter family and the organic anion transporting polypeptide family namely
MRP2, P-gp, BCRP, and OATP1B3. Speciﬁc inhibitors for these transporters (BCRP:
10 μmol/L fumitremorgin C; P-gp: 100 μmol/L verapamil; OATP1B3: 1 μmol/L
bromosulfophthalein; MRP2: 50 μmol/L MK571) signiﬁcantly reduced their activity
(n=6, *pb0.05 vs. control, ANOVA with Bonferroni adjustment) as shown by the
increase of intracellular ﬂuorescence for MRP2, P-gp and BCRP inhibition as well as the
decrease of intracellular ﬂuorescence for OATP1B3 inhibition. However, none of the
investigated DCAs signiﬁcantly altered transport via these transporters. Data are
presented as change of intracellular ﬂuorescence in percent of the untreated control
and are expressed as mean±S. D.on Na+ and was decreased in the presence of the cyclochrome c
oxidase inhibitor NaCN (2 mmol/L). The OAT substrate probenecid
(2 mmol/L) had no effect on 14C-GA uptake (Fig. 8a). Permeation of
this DCA across hCPEC was neither inhibitable by probenecid nor
dependent on the Na+ gradient or on energy (Fig. 8b) suggesting non-
speciﬁc permeation.
4. Discussion
The BBB is a central biochemical interface between the systemic
circulation and the CNS gate-keeping the transport of hydroxyphilic
compounds to and from the brain. The transport of many drugs and
hydrophilic nutrients including monocarboxylic acids and amino
acids has been intensively studied (for review, e.g. [34,35]). In
contrast, little is known about the transport of DCAs across the BBB
which is much more limited than those of amino acids and
monocarboxylic acids [2,19,36]. Accumulation of GA, 3-OH-GA, and
MMA is the biochemical hallmark of the inherited organic acidurias
GA-I and MMAuria and is involved in their neuropathogenesis.
Therefore, we studied the transport of these DCAs across cultivated
pBCEC and hCPEC, in vitro models for the mammalian BBB and BCB
respectively.
Our study shows that there is a speciﬁc transport system for DCAs
at the BBB, OAT1 and OAT3, but with a low capacity and that there is
virtually no transport of DCAs across the choroid plexus.
4.1. Low capacity DCA transport across the BBB via OAT1 and OAT3
Transport of DCAs can be mediated by members of the SLC22 (OAT
1, 3 and 4; [22]) and SLC13 (NaDC 1 and 3; [23]) families. OATs couple
the import of monocarboxylic acids, such as PAH, to the export of
DCAs and, thereby, are energy-independent. The import of monocar-
boxylic acids via OATs, however, is indirectly coupled to the Na+
gradient by NaDCs [37,38]. NaDCs co-import DCAs and Na+
replenishing the intracellular pool of DCAs (tertiary active transport).
NaDCs and OATs have been shown to be co-expressed in renal
proximal tubular cells [39] and choroid plexus [20]. At the BBB,
however, only functional OAT3 has as yet been identiﬁed [26,27].
Using RT-PCR studies and Western blotting we demonstrated that
OAT3 and OAT1 but not NaDCs are expressed in pBCEC. In vitro
transport studies in pBCEC demonstrated that efﬂux transport (CNS to
Fig. 8. a,b DCA transport across human plexus choroideus. 8a) Uptake of 14C-GA was
strongly dependent on Na+ and was decreased in the presence of the cytochrome c
oxidase inhibitor NaCN (2 mmol/L). The OAT substrate probenecid (2 mmol/L) had no
effect on 14C-GA uptake (after 20 min; *pb0.05 vs. GA alone, ANOVA with Bonferroni
adjustment) 14C-GA uptake is expressed as counts per minute detected in the cell and
data are expressed as mean±S. D. representing n=3 independent experiments.
8b) Permeation of 14C-GA across hCPEC was neither inhibitable by probenecid nor
dependent on the Na+ gradient or on ATP. Data are presented as permeation over the
time and, for legibility, are expressed as mean; n=3 independent experiments; C0,
initial concentration of 14C-GA in the donor compartment.
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inﬂux (plasma to CNS) which was close to the rate of non-speciﬁc
paracellular permeation. This is in line with previous studies showing
that OAT3 is mainly expressed at the CNS site of brain endothelial cells
[26,27]. Consistently with the transport characteristics of OAT1 and
OAT3, cellular uptake of GA was cis-inhibited by probenecid, estrone
sulfate and, taurocholate. Estrone sulfate and probenecid revealed a
stronger cis-inhibitory effect than taurocholate. This ﬁnding high-
lights that OAT1 and 3 are involved in DCA uptake since taurocholate
is mainly a substrate of OAT3 whereas probenecid and estrone sulfate
are inhibitor and substrate respectively of OAT1 and 3. Efﬂux
transport of GA, 3-OH-GA, and MMA across pBCEC was cis-inhibited
by the OAT1 and 3 substrate PAH and was energy-independent.
Studying DCA transport in representative members of the ATP-
binding cassette transporter family and the organic anion transport-
ing polypeptide family, i.e. MRP2, BCRP, P-gp, and OATP1B3, we did
not ﬁnd evidence that DCAs are substrates of these transporter
families. Further, we showed that GA, 3-OH-GA, or MMA are not
cytotoxic to pBCEC which would result in increased non-speciﬁc
paracellular permeation. A breakdown of the BBB integrity has been
postulated to play a role in the pathophysiology of GA-I [14,17],
whereas this mechanism was not conﬁrmed by another study [19]. Inline with the latter study, GA, 3-OH-GA, and MMA did not show
cytotoxic effect on pBCEC even after one week of incubation at
pathophysiologically relevant concentrations.
Interestingly, our study demonstrates that transport of GA, 3-OH-
GA, and MMA across pBCEC is Na+-dependent. Since we did not ﬁnd
evidence that NaDCs are expressed in pBCEC, we hypothesize that the
import of DCAs via OAT1 or OAT3 is also coupled to a system that
replenishes the cellular drain of monocarboxylic acids. This mono-
carboxylic acid transport system remains to be elucidated. A putative
candidate is the monocarboxylic acid/proton co-transporter MCT1
which is known to play an important role in the transport of
monocarboxylic acids across the BBB [40]. Since Na+-free medium
would inhibit Na+/H+ exchangers, impair MCT1 transport and,
subsequently, reduce the transport of DCAs via OAT1 and 3 due to a
lack of suitable exchange molecules, our observation of Na+-
dependent transport of DCAs via OAT1 and 3 very well ﬁts to a
functional coupling of OAT1 and 3 with MCT1 at the BBB.
4.2. Intracellular trapping of DCAs: discrepancies of the apical and
basolateral BBB site
Uptake of GA in pBCEC was time-dependent and revealed
Michaelis–Menten-like kinetics but with a slow and linear transport
phase instead of a plateau. The simultaneously recorded transcellular
transport was linear over the time. These ﬁndings suggest that GA is
effectively imported into the cell, whereas it is only weakly exported
causing intracellular accumulation of GA and, subsequently, decrease
of cellular GA uptake. Consistent with this notion, ﬂuorescein efﬂux
studies showed increased transport of this monocarboxylic acid when
pBCEC were preconditioned with a DCA and unchanged transport
when DCA transport had been inhibited by PAH and replacement of
Na+ by NMG. Interestingly, ﬂuorescein transport across pBCEC was
also inhibited after pre-incubation with DCA and NaCN, a condition
that did not inhibit DCA transport. This ﬁnding demonstrates that at
least at one site of the pBCEC a transporter other than OATs mediates
ﬂuorescein transport. MRP2 is a likely candidate for alternative
ﬂuorescein transport, since glutathione-conjugated ﬂuorescein is a
known substrate of MRP2 which is expressed at the apical site of the
BBB [41]. Therefore, our data suggest that ﬂuorescein is imported via
OAT1 or OAT3, is conjugated to glutathione by the glutathione-S-
transferase and is ﬁnally exported by MRP2. The transport rate of
ﬂuorescein was approximately two times higher than the DCA
transport rate providing further evidence that transport across the
apical BBB site is the rate limiting step in DCA transport.
4.3. DCA transport systems are restricted to the CSF site of choroid plexus
Finally, we studied the transport of 14C-GA across hCPEC, an in vitro
model of the BCB. Our experiments revealed transport characteristics
for the uptake of 14C-GA that are in line with previously published
data showing that OAT1 and 3 as well as NaDC1 and 3 are expressed at
the CSF site of the choroid plexus [20]. Efﬂux of this DCA was
signiﬁcantly higher than inﬂux and only uptake at the CSF site
revealed speciﬁc transport characteristics. The uptake was strongly
dependent on the Na+ gradient and inhibited by NaCN indicating an
involvement of NaDC1 and 3. In contrast, the uptake was not affected
by probenecid demonstrating that OATs do not mediate the cellular
import of DCAs when NaDCs are co-expressed and functional. Though
we also found a permeation of 14C-GA across hCPEC, it was neither
dependent on energy or Na+ nor inhibited by probenecid. This ﬁnding
highlights that there is no active transport of DCAs across hCPEC. In
combination with the fact that the BBB surface is several thousand
times larger than the surface of the choroid plexus [21], it is unlikely
that neurotoxic DCAs accumulating inMMAuria or GA-I are effectively
transported across the choroid plexus.
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option for organic acidurias?
In conclusion, our study indicates that OAT1 and OAT3 participate
in the efﬂux GA, 3-OH-GA, and MMA across the BBB. The low
permeability of the BBB for DCAs is likely to be caused by a weak OAT1
and OAT3 expression at the apical site of BCEC. Trans-stimulation of
the DCA transport via OAT1 and OAT3 by monocarboxylic acids such
as PAH or upregulation of OAT1 and OAT3 at the BBB should be
considered as novel therapeutic approach to decrease the intracere-
bral concentrations of neurotoxic DCAs which are trapped within the
brain compartment [2,18]. Interestingly, dihydrotestosterone has
been shown to upregulate OAT3 expression in immortalized rat
BCEC via androgen receptor [42]. It should be tested whether this
strategy is effective and safe and whether it could be added to current
metabolic treatment which aims to reduce the cerebral de novo
synthesis of neurotoxic DCAs.
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